Professional Documents
Culture Documents
Peds 2022058859
Peds 2022058859
PEDIATRICS Volume 150, number 3, September 2022:e2022058859 FROM THE AMERICAN ACADEMY OF PEDIATRICS
Downloaded from http://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2022-058859/1346778/peds_2022058859.pdf
by guest
worked from 2014 to 2022 to Previous Guidelines tables included in Appendix B and in
review new evidence and to identify The 2004 guideline focused on the accompanying technical
opportunities to clarify and improve infants $35 weeks’ gestation. This report.11 In addition, the committee
the 2004 guideline. This report gestational age range includes most reviewed guidelines from the
underwent extensive peer review by newborn infants cared for, and Northern California Neonatal
a wide array of clinicians and subsequently followed by, general Consortium12 and the Academy of
experts in neonatal pediatricians and other primary care Breastfeeding Medicine.13 Because
hyperbilirubinemia and by parents clinicians on well newborn services the new evidence is insufficient to
of children with kernicterus. derive specific treatment thresholds
or mother-baby care units. The 2004
guideline made recommendations for by quantitatively estimating the
The committee recognizes that in risks and benefits of different
primary prevention (eg, maternal
the United States and other high- approaches to care, the committee
Rh typing and treatment) and
resource countries, the began with the previous AAP
secondary prevention (eg, risk-
recommended management of guidelines. On the basis of an
factor assessment and close
hyperbilirubinemia and the risk of evaluation of evidence published
monitoring for the development of
kernicterus can differ significantly since 2004, the committee raised
from countries with more limited hyperbilirubinemia, and, when
necessary, treatment). the phototherapy thresholds by a
resources. The management of
narrow range that the committee
hyperbilirubinemia can also vary
In 2009, a commentary describing considered to be safe. The
among high-resource countries
several clarifications and committee also used new research
where early discharge from the
modifications6 to the 2004 clinical findings to revise the risk-
mother-baby unit is less common.
practice guideline was published. assessment approach based on the
The committee recommends caution
These included clarifying the hour-specific bilirubin
and incorporation of local expertise
distinction between concentration and the approach to
in adapting these guidelines for use
“hyperbilirubinemia risk factors,” rapidly address elevated bilirubin
outside the United States.
which increase the risk of concentrations, defined as
This clinical practice guideline subsequent hyperbilirubinemia, and “escalation of care.”
provides specific recommendations “hyperbilirubinemia neurotoxicity
where evidence or significant risk factors,” which increase the risk I. PREVENTION OF
clinical experience suggests the of bilirubin neurotoxicity. A new HYPERBILIRUBINEMIA
benefit of the clinical action. In some recommendation was for universal
predischarge bilirubin screening A. Preventing Hyperbilirubinemia
cases, options for clinical care Associated With Isoimmune
delivery are provided when the with measures of total serum
Hemolytic Disease
evidence or clinical experience is bilirubin (TSB) or transcutaneous
less certain. For selected bilirubin (TcB) linked to specific Prevention of hyperbilirubinemia
recommendations that are central to recommendations for follow-up. begins in pregnancy by recognizing
this guideline, the subcommittee Although it is difficult to determine and treating women who are at risk
reports the aggregate quality the direct impact of these for developing antibodies to red cell
evidence and the strength of the recommendations, the incidence of antigens, which can lead to
recommendation according to the hazardous hyperbilirubinemia, hemolytic disease of the newborn
AAP policy statement “Classifying defined as TSB $30 mg/dL,7 (ie, isoimmune hemolytic disease). If
Recommendations for Clinical decreased in at least 3 large US the mother was not screened for
Practice Guidelines.”5 These health systems after the adoption of anti-erythrocyte antibodies during
recommendations are formatted as universal predischarge bilirubin pregnancy, evaluation and treatment
Key Action Statements (KAS) for screening with closer postdischarge should occur shortly after delivery.
easy identification, and the evidence follow-up.8–10 The American College of
tables supporting them appear in Obstetricians and Gynecologists
Appendix B. Note that throughout Evidence Leading to Changes recommends that pregnant women
the guideline, the term “parent” is Since the publication of the previous be tested to determine their ABO
used to represent the caregiver(s) guideline, the evidence base blood group and Rh(D) type and
responsible for the infant and regarding the monitoring and receive an antibody screen to
“mother” is used to represent the treatment of hyperbilirubinemia has determine the need for Rh(D)
birthing and/or breastfeeding expanded. Key new research immunoglobulin (RhIG) and to
parent. findings appear in the evidence assess the potential for isoimmune
Start
(all newborns)
FIGURE 1
Approach to identify newborns with maternal anti-erythrocyte antibodies and to guide early management.15
24
22
20
Total Serum Bilirubin (mg/dL)
18
14 Gestational Age
≥ 40 Weeks
12 39 Weeks
38 Weeks
37 Weeks
10
36 Weeks
35 Weeks
8
6
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 252 264 276 288 300 312 324 336
(1d) (2d) (3d) (4d) (5d) (6d) (7d) (8d) (9d) (10d) (11d) (12d) (13d) (14d)
Age – hours
(days)
FIGURE 2
Phototherapy thresholds by gestational age and age in hours for infants with no recognized hyperbilirubinemia neurotoxicity risk factors other than gesta-
tional age. These thresholds are based on expert opinion rather than strong evidence on when the potential benefits of phototherapy exceed its potential
harms. Use total serum bilirubin concentrations; do not subtract direct-reacting or conjugated bilirubin from the total serum bilirubin. In rare cases of
severe hyperbilirubinemia in which the direct-reacting or conjugated bilirubin exceeds 50% of the TSB, consult an expert. Note that infants <24 hours old
with a TSB at or above the phototherapy threshold are likely to have a hemolytic process and should be evaluated for hemolytic disease as described in rec-
ommendation 14. Hyperbilirubinemia neurotoxicity risk factors include gestational age <38 weeks; albumin <3.0 g/dL; isoimmune hemolytic disease,
glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other hemolytic conditions; sepsis; or any significant clinical instability in the previous 24 hours.
See Supplemental Fig 1.
18
16
Total Serum Bilirubin (mg/dL)
12
Gestational Age
10
≥ 38 Weeks
37 Weeks
8 36 Weeks
35 Weeks
6
4
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 252 264 276 288 300 312 324 336
(1d) (2d) (3d) (4d) (5d) (6d) (7d) (8d) (9d) (10d) (11d) (12d) (13d) (14d)
Age – hours
(days)
FIGURE 3
Phototherapy thresholds by gestational age and age in hours for infants with any recognized hyperbilirubinemia neurotoxicity risk factors other than gesta-
tional age. These thresholds are based on expert opinion rather than strong evidence on when the potential benefits of phototherapy exceed its potential
harms. Use total serum bilirubin concentrations; do not subtract the direct-reacting or conjugated bilirubin from the total serum bilirubin. In rare cases of
severe hyperbilirubinemia in which the direct-reacting or conjugated bilirubin exceeds 50% of the TSB, consult an expert. Hyperbilirubinemia neurotoxicity
risk factors include gestational age <38 weeks; albumin <3.0 g/dL; isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency,
or other hemolytic conditions; sepsis; or any significant clinical instability in the previous 24 hours. See Supplemental Fig 2.
the treatment threshold should also important to recognize that the TSB concentration no more than
consider the risk of overtreatment on amount of irradiance received by 1 mg/dL above the phototherapy
the infant and family. Whenever infants is higher directly below the treatment threshold (Fig 2;
possible, phototherapy should be light source than at the periphery.104 Supplemental Table 1 and
provided in the mother’s room or in a The irradiance levels recommended Supplemental Fig 1)
room in which the mother can remain in these guidelines refer to those An LED-based phototherapy de-
with the infant. measured below the center of the vice will be available in the home
light source. without delay
To optimize the effectiveness of TSB can be measured daily
inpatient phototherapy, hospitals KAS 11: For newborn infants who
should verify that phototherapy have already been discharged and Home phototherapy can be less costly
systems provide the intended then develop a TSB above the and disruptive to family routines and
irradiance, following the phototherapy threshold, breastfeeding and may help improve
recommendations of the treatment with a home LED-based bonding and reduce stress compared
manufacturer. Although the routine phototherapy device rather than with readmission for phototherapy.106
measurement of irradiance in infants readmission to the hospital is an However, its effectiveness depends on
receiving phototherapy is option for infants who meet the the quality of the home phototherapy
encouraged, studies of this issue in following criteria.104,105 device as well as the ability of the
the United States are lacking. (Aggregate Evidence Quality family to appropriately use it.
However, studies in the Netherlands Grade D, Option) Therefore, caution is needed when
have found that suboptimal considering home phototherapy.
phototherapy dosages are Gestational age $38 weeks Furthermore, home phototherapy is
common.102 Different irradiance $48 hours old not recommended for infants with
measurement devices can lead to Clinically well with adequate any hyperbilirubinemia neurotoxicity
varying results,83 so it is reasonable feeding risk factor.
to follow the manufacturer No known hyperbilirubinemia
recommendations regarding how and neurotoxicity risk factors (Table 2) Home phototherapy should not be
when to measure irradiance. It is No previous phototherapy used if there is any question about
Start
(TSB exceeds
escalation of care level)
FIGURE 4
Approach to escalation of care. The escalation-of-care threshold is 2 mg/dL below the exchange transfusion threshold. IVIG, intravenous immune globulin;
B/A, bilirubin to albumin ratio.
24
20
Gestational Age
≥ 38 Weeks
18 37 Weeks
36 Weeks
35 Weeks
16
14
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 252 264 276 288 300 312 324 336
(1d) (2d) (3d) (4d) (5d) (6d) (7d) (8d) (9d) (10d) (11d) (12d) (13d) (14d)
Age − hours
(days)
FIGURE 5
Exchange transfusion thresholds by gestational age for infants with no recognized hyperbilirubinemia neurotoxicity risk factors other than gestational age.
See Fig 4, which describes escalation of care. These thresholds are based on expert opinion rather than strong evidence on when the potential benefits of
escalation of care exceed its potential harms. The stippled lines for the first 24 hours indicate uncertainty because of the wide range of clinical circumstan-
ces and responses to intensive phototherapy. Use total serum bilirubin concentrations; do not subtract direct bilirubin from the total serum bilirubin. In
rare cases of severe hyperbilirubinemia in which the direct-reacting or conjugated bilirubin exceeds 50% of the TSB, consult an expert. Hyperbilirubinemia
neurotoxicity risk factors include albumin <3.0 g/dL; isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other hemo-
lytic conditions; sepsis; or any significant clinical instability in the previous 24 hours. See Supplemental Fig 4.
proceed according to the section escalation-of-care guidelines should deferred while continuing
“C. Monitoring Infants Receiving continue to be followed if IVIG is used. intensive phototherapy and
Phototherapy.” (Aggregate following the TSB every 2 hours
Evidence Quality Grade X, KAS 22: An urgent exchange until the TSB is below the
Recommendation) transfusion should be performed escalation of care threshold.
for infants with signs of (Aggregate Evidence Quality
KAS 21: Intravenous immune intermediate or advanced stages Grade C, Recommendation)
globulin (IVIG; 0.5 to 1 g/kg) over of acute bilirubin encephalopathy
2 hours may be provided to (eg, hypertonia, arching, Cross-matched washed packed red
infants with isoimmune hemolytic retrocollis, opisthotonos, high- blood cells mixed with thawed adult
disease (ie, positive DAT) whose pitched cry, or recurrent apnea). fresh-frozen plasma to a hematocrit
TSB reaches or exceeds escalation (Aggregate Evidence Quality approximating 40% is preferred for
of care threshold. The dose can be Grade C, Recommendation) exchange transfusions.127–129 The
repeated in 12 hours. (Aggregate additional albumin-containing fresh-
Evidence Quality Grade C, Option) KAS 23: An urgent exchange frozen plasma that infants receive by
transfusion should be performed keeping the hematocrit close to 40%
The effectiveness of IVIG to prevent the for infants if the TSB is at or will augment bilirubin removal.127–129
need for an exchange transfusion is above the exchange transfusion
unclear. Observational studies suggest threshold. If, while preparing for The bilirubin to albumin ratio can
an association between IVIG and the exchange transfusion but be used in conjunction with the TSB
necrotizing enterocolitis. A detailed before starting the exchange level in determining the need for
review of the potential benefits and transfusion, a TSB concentration exchange transfusion. The bilirubin
harms is provided in the technical is below the exchange transfusion to albumin ratio treatment
report. Factors that should be threshold and the infant does not threshold for exchange transfusion,
considered include response to show signs of intermediate or measured as TSB (measured in mg/
phototherapy, TSB rate of increase, and advanced stages of acute bilirubin dL) divided by serum albumin
the challenge of providing a timely encephalopathy, then the (measured in g/dL), varies by gestational
exchange transfusion. All aspects of the exchange transfusion may be age and risk. In addition to the criteria
22
Total Serum Bilirubin (mg/dL)
20
Exchange Transfusion Thresholds: 1 or More Hyperbilirubinemia Neurotoxicity Risk Factors
18
Gestational Age
16 ≥ 38 Weeks
37 Weeks
36 Weeks
35 Weeks
14
12
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 252 264 276 288 300 312 324 336
(1d) (2d) (3d) (4d) (5d) (6d) (7d) (8d) (9d) (10d) (11d) (12d) (13d) (14d)
Age – hours
(days)
FIGURE 6
Exchange transfusion thresholds by gestational age for infants with any recognized hyperbilirubinemia neurotoxicity risk factors other than gestational
age. See Fig 4, which describes escalation of care. These thresholds are based on expert opinion rather than strong evidence on when the potential benefits
of escalation of care exceed its potential harms. The stippled lines for the first 24 hours indicate uncertainty because of the wide range of clinical circum-
stances and responses to intensive phototherapy. Use total serum bilirubin concentrations; do not subtract direct bilirubin from the total serum bilirubin.
In rare cases of severe hyperbilirubinemia in which the direct-reacting or conjugated bilirubin exceeds 50% of the TSB, consult an expert. Hyperbilirubine-
mia neurotoxicity risk factors include albumin <3.0 g/dL; isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other he-
molytic conditions; sepsis; or any significant clinical instability in the previous 24 hours. See Supplemental Fig 5.
described above, an exchange assessing the risk of developing measurements (Fig 7). This
transfusion may be considered if the clinically significant approach incorporates both gestational
bilirubin to albumin ratio is: hyperbilirubinemia based on a age and other hyperbilirubinemia
nomogram using postnatal age in neurotoxicity risk factors into the
$8.0 if the gestational age is hours and the bilirubin concentration decision-making process. This
$38 weeks’ gestation and there coupled with the presence or approach has been studied in newborn
are no hyperbilirubinemia neuro- absence of hyperbilirubinemia risk infants in the Kaiser Permanente
toxicity risk factors, or factors to determine the need for Northern California hospitals.72 The
$7.2 if the gestational age is monitoring. Those follow-up timing of postdischarge follow-up
$38 weeks’ gestation and there recommendations used a previous (Fig 7) should also take into
is at least 1 hyperbilirubinemia risk nomogram (Fig 2 in the 2004 consideration the presence of other
neurotoxicity risk factor, or guideline, based on the 1999 study of hyperbilirubinemia risk factors
$7.2 if the gestational age is 35 Bhutani et al131) that did not take (Table 1).
through 37 weeks’ gestation with gestational age and
no hyperbilirubinemia neurotox- hyperbilirubinemia neurotoxicity risk These follow-up guidelines are
icity risk factor, or factors into account and was created based only on the management of
$6.8 if the gestational age is 35 from a study population that hyperbilirubinemia. Other
through 37 weeks’ gestation and excluded DAT positive infants. considerations that may influence
at least 1 hyperbilirubinemia the timing of follow-up include
neurotoxicity risk factor.130 The current guideline recommends gestational age, postnatal age,
using the difference between the assessment of breastfeeding,
IV. POSTDISCHARGE FOLLOW-UP bilirubin concentration and the weight loss from birth weight, and
phototherapy threshold at the time assessment of the well-being of the
A. Timing of Follow-Up After of measurement to determine the infant and parents.
Discharge interval between discharge and
The 2004 guideline3 and subsequent follow-up and the need for KAS 24: Beginning at least
2009 clarification6 recommended additional TSB or TcB 12 hours after birth, if discharge
FIGURE 7
Flow diagram for infants during the birth hospitalization to determine postdischarge follow-up for infants who have not received phototherapy.
a
Use clinical judgment and shared decision making to determine when to repeat the bilirubin measure within this 4 to 24 hour time window.
b
Clinical judgment decisions should include physical examination, the presence of risk factors for the development of hyperbilirubinemia (Table 1) or
hyperbilirubinemia neurotoxicity risk factors (Table 2), feeding adequacy, weight trajectory, and family support.
is being considered, the V. HOSPITAL POLICIES AND Hospitals should have systems to
difference between the bilirubin PROCEDURES verify that appropriate irradiance is
concentration measured closest Hospitals and other types of birthing delivered and should follow the
to discharge and the centers should have clearly established recommendations of the
phototherapy threshold at the policies and procedures to help all phototherapy system manufacturer.
time of the bilirubin infants receive optimal care to prevent Hospitals are encouraged to have a
measurement should be kernicterus. Clinicians should family-centered approach to
calculated and used to guide document activities specifically related phototherapy that includes
follow-up, as detailed in Fig 7. to this clinical practice guideline in the providing phototherapy in the
(Aggregate Evidence Quality medical record. mother’s room, when possible, to
Grade C, Recommendation) allow for bonding and breastfeeding.
Nursing protocols with standing
Figure 7 is only applicable for orders should be established for All facilities treating infants without
infants at least 12 hours after the physical assessment of the equipment or personnel to
birth and for infants who have not neonatal jaundice and the escalate care should have written
received phototherapy before circumstances in which the nursing plans for rapid and safe transfer of
discharge. Insufficient information staff can obtain a TcB or TSB infants who might require exchange
is available to provide discharge measurement. This should include transfusion. These plans should
follow-up guidance based on TcB obtaining a TcB or TSB if jaundice include the ability to provide
or TSB measured before 12 hours is noted within the first 24 hours phototherapy during transfer.
after birth. Any infant discharged after birth.
before 12 hours of age should Facilities that provide care for
have a follow-up bilirubin All facilities treating infants should newborn infants should have a
measure between 24 and 48 hours have the necessary equipment to mechanism, when needed, for infants to
of age. provide intensive phototherapy. have a follow-up TcB or TSB measured
Clinical practice guidelines from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical
practice guidelines from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.
The guidance in this document does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual
circumstances, may be appropriate.
All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.
DOI: https://doi.org/10.1542/peds.2022-058859
Address correspondence to Alex R. Kemper, MD. Email: alex.kemper@nationwidechildrens.org
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2022 by the American Academy of Pediatrics
FUNDING: No external funding.
FINANCIAL/CONFLICT OF INTEREST DISCLOSURES: Dr Newman reported providing expert witness consultation in medical malpractice litigation. Dr Maisels reported providing
expert witness review and testimony in kernicterus medical malpractice litigation. Dr Watchko disclosed a financial relationship with McGraw Hill. Dr Grout reported receiving
grant funding from Pfizer for a non-pediatric study. Dr Bogen disclosed a Board of Directors relationship with Mid-Atlantic Mothers’ Milk Bank. No other disclosures were
reported.
COMPANION PAPERS: Companions to this article can be found online at: www.pediatrics.org/cgi/doi/10.1542/peds.2022-058865, www.pediatrics.org/cgi/doi/10.1542/peds.2022-2022-
058918, and www.pediatrics.org/cgi/doi/10.1542/peds.2022-058020.